# SBRT-AMICO (NCT05915442)

> Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05915442
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Catherine Spina
- Conditions: Oligometastatic Prostate Cancer
- Interventions: Quemliclustat; Etrumadenant; Zimberelimab; Stereotactic Body Radiation Therapy
- Enrollment: 23
- Primary outcome: Biochemical recurrence-free survival at 12-months

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sbrt-amico-nct05915442